Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Frontiers in Pharmacology|January 11, 2014
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressantsCaroline A Browne, Irwin Lucki
Pharmacology & Therapeutics|May 4, 2019
Targeting opioid dysregulation in depression for the development of novel therapeuticsCaroline A Browne, Irwin Lucki
Handbook of Experimental Pharmacology|February 13, 2021
Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive DisorderCaroline A Browne, Hildegard Wulf, Irwin Lucki
Frontiers in Pain Research (Lausanne, Switzerland)|February 16, 2026
The nonhallucinogenic ketamine metabolite (2R,6R)-hydroxynorketamine is a novel analgesic in animal models of painBruno Carabelli, Caroline A Browne, Irwin Lucki
European Journal of Pharmacology|January 29, 2020
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depressionCaroline A Browne, Tiffany Smith, Irwin Lucki
Frontiers in Synaptic Neuroscience|December 25, 2018
Dysregulation of the Lateral Habenula in Major Depressive DisorderCaroline A Browne, Robert Hammack, Irwin Lucki
Nurse Education Today|June 11, 2015
International clinical placements for Australian undergraduate nursing students: A systematic thematic synthesis of the literatureCaroline A Browne, Catherine M Fetherston, Kristina Medigovich
Annual Review of Pharmacology and Toxicology|January 10, 2020
Kappa Opioid Receptor Antagonists as Potential Therapeutics for Stress-Related DisordersMoriah L Jacobson, Caroline A Browne, Irwin Lucki
Harvard Review of Psychiatry|January 9, 2020
Novel Targets to Treat Depression: Opioid-Based TherapeuticsCaroline A Browne, Moriah L Jacobson, Irwin Lucki
Pageof 4